At present, five different ALK‐Tyrosine kinase inhibitors (ALK‐TKIs) have been approved by food and drug administration (FDA) to treat ALK‐positive non‐small cell lung cancer (NSCLC) patients (Figure 1). This evidence concerns the gene ALK and non-small cell lung carcinoma.